Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non‐small‐cell lung cancer treated with pembrolizumab

Immune checkpoint inhibitors, such as pembrolizumab, are revolutionizing therapeutic strategies for different cancer types, including non‐small‐cell lung cancer (NSCLC). However, only a subset of patients benefits from this therapy, and new biomarkers are needed to select better candidates. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondelo‐Macía, Patricia, García‐González, Jorge, León‐Mateos, Luis, Anido, Urbano, Aguín, Santiago, Abdulkader, Ihab, Sánchez‐Ares, María, Abalo, Alicia, Rodríguez‐Casanova, Aitor, Díaz‐Lagares, Ángel, Lago‐Lestón, Ramón Manuel, Muinelo‐Romay, Laura, López‐López, Rafael, Díaz‐Peña, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564635/
https://www.ncbi.nlm.nih.gov/pubmed/34465006
http://dx.doi.org/10.1002/1878-0261.13094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564635/
https://www.ncbi.nlm.nih.gov/pubmed/34465006
http://dx.doi.org/10.1002/1878-0261.13094

Ejemplares similares